

# #endHIV


2016 ANNUAL REPORT



ABZYME  
RESEARCH  
FOUNDATION



You  | **#HIVBeats**  
*Watch now!*



## CONTENTS

Letter From Our Co-Chairs	04
Letter From Our Founder/Executive Director	06
Progress and Milestones	7, 8
Fiscal Breakdown (How much we took in, what we spent it on, and what we reserved)	09
Executive Board	10, 11
Supporter List	12



**Adam MacLean**  
Co-Chair



**Valerie Kerr**  
Co-Chair

## Letter From Our Co-Chairs Adam MacLean & Valerie Kerr

Dear Friends and Supporters,

2016 was an incredible year for Abzyme Research Foundation and it's our pleasure to highlight the strategic advancements we've made in our mission to end HIV/AIDS. First and foremost we're thrilled to share that we had our strongest fund-raising year to date, raising over \$1,000,000 to support our awareness, and research initiatives. As a relatively young charity we are also proud of our 76% direct to program rate. Below is additional detail on our two main program initiatives.

### **ADVANCING OUR HIV E-VACCINE INTO HUMAN CLINICAL TRIALS:**

In October of 2016, the Abzyme Research Foundation made its largest Program Related Investment ever to begin the manufacturing scale-up of the E-vaccine. This step is a prerequisite of which leads us to be granted FDA permission to begin human trials. While several steps remain before we can submit our final application to the FDA (IND submission), it is our hope that we are ready to present in Q4 2017.

### **ARTS AND CELEBRITY CAMPAIGNS TO RAISE HIV AWARENESS AND RAISE FUNDS**

In June of 2016 ARF launched the second segment of the #endHIV Campaign with the Kaiser Family Foundation, YouTube, and Gilead Pharmaceuticals. This campaign - HIV BEATS - was viewed over one million times in its first month. Praised by young audiences and government health offices alike, HIV Beats was heralded as the best HIV PSA series of 2016 by HealthLine.

Simultaneously, ARF released a choreographed short film narrated by Julianne Moore, *HOSTAGE*. *OUT* Magazine called the work "A mix of beautiful and lithe dancers against a white background in a physical storytelling piece that covers the beginning, middle, and hopefully end of the AIDS epidemic on a cellular level." After seeing the work, PULSE ART FAIR Miami invited ARF to be the inaugural charitable partner during Art Basel Miami. The interactive partnership engaged over 25,000 people to our work and raised thousands of dollars.

This year it is our goal to raise the final funds needed to get the E-vaccine cleared for human trials, build additional consensus around our groundbreaking science, and create even more compelling artistic engagements to inspire people to fight for the end of HIV/AIDS.

Please join us for this exciting journey.

Best,  
Valerie Kerr & Adam MacLean,  
Co-Chairs, Abzyme Research Foundation



**Zachary Barnett**  
**Founder and Executive Director**  
**Abzyme Research Foundation**

# Letter From Abzyme Research Foundation Founder/Executive Director

Dear Friends and Supporters,

January 15, 2016

2016 was an incredible year for the Abzyme Research Foundation and our #endHIV Campaign. It brings me immense joy to look back and to share some of the incredible milestones we have crossed in the space of one short year.

The most striking change was in our ability to fundraise large gifts and grants, starting with a \$150,000 grant from Gilead in February to produce the #HIV Beats PSA series with YouTube and Greater Than AIDS. In April we got our first 6-figure pledge to support our advancement of the HIV E-Vaccine from the Livel Foundation, and at the end of the year we were thrilled to announce a \$400,000 gift in memory of Dr. Scott Stansbury who passed of AIDS related illnesses in 1995 (see the announcement on pg 7). In all we raised over \$1.1 million in 2016 with a direct to program rate of 76%.

Among all those successes there have be challenges and setbacks. We have seen our costs to manufacture the E-vaccine and prepare it for human trials rise sharply. These increased costs have cause some delays but the project is still moving consistently forward. On the next page is the most recent update to our milestones to test a new potential cure for AIDS in our Progress and Milestones section.

This coming year we will be growing in both breadth and depth. This summer we will launch our largest arts campaign to-date powered with a dazzling group of female celebrities. Internally we are growing the board to better connect with family foundations, our scientific critics, and partner NGOs that can help us re-imagine a pathway to a world without HIV/AIDS.

Thank you for your incredible support this past year, and I hope that you are excited to take the next steps with us. Together we can #endHIV.

Yours,  
Zachary Barnett  
Founder/Executive Director

# Progress and Milestones for the #ENDHIV Campaign

In 2017, we hope to obtain permission from the FDA to start human trials with the E-vaccine, developed by Dr. Sudhir Paul, and being developed by Abzyme Research Foundation to test it's potential as a functional cure.

An FDA Phase 1 Trial, which will accomplish two critical goals. Most importantly, it will allow us to determine if antibodies produced in humans who receive the vaccine are also able to neutralize diverse strains of HIV across the globe as tested in infected human tissue samples. Second, it will make the vaccine more eligible to attract traditional avenues of funding. At this moment, the vaccine is ready for trial; it just needs the funding to get there.

Your support helps fund the steps needed to clear the vaccine for human trials as laid out by the Food and Drug Administration. Only further research and published peer-reviewed data will silence any groups whom doubt the validity of this powerful new approach to curing AIDS and vaccinating against HIV.

## Project Milestones

### Milestone 1

Raise \$100,000 to initiated the process of securing permission for a human HIV vaccine study from the FDA, and price out manufacturing and final FDA filings. COMPLETE



### Milestone 2

Raise \$2,000,000 to scale up commercial grade manufacturing, quality assurance testing, and present final FDA data for permission to move into human trials. Your support of this critical phase will enable us to move into commercial manufacturing for this potential HIV cure and remove the remaining bureaucratic roadblocks to a human trial. Our biggest hurdle is credibility, and securing FDA approval for trial will allow our celebrity fueled public funding campaign to be successful. (40% Complete)



### Milestone 3

Raise \$3,000,000 to fund the Phase I human trial. ARF has created a powerful media campaign featuring Julianne Moore, and other incredible celebrities that will assist in public facing crowd-funding and corporate sponsorship.

If you think of a brand, individual, or a Foundation that would be interested in learning more about funding and partnership opportunities, Please contact [zach@endhiv.com](mailto:zach@endhiv.com).



# Financial Highlights

For the Year Ended December 31, 2016

	Unrestricted	Temporarily Restricted	Total
<b>Public Support &amp; Revenue</b>			
Grants & Contributions			
Foundations & Trusts	107,071	660,852	767,923
Corporations	72,840	200,000	272,840
Individuals	37,850		37,850
In-kind Contributions	20,400		20,400
Special Events & Other Income*	15,075		15,075
<b>Total Public Support &amp; Revenue</b>	<b>253,236</b>	<b>860,852</b>	<b>1,114,088</b>
Net Assets Released From Restrictions	252,318	(252,318)	0
Total Revenue After Releases	505,554	608,534	1,114,088
<b>Expenses</b>			
Program Services	336,774		336,774
Supporting Services			
Administration & General	52,309		52,309
Fundraising	49,523		49,523
Total Supporting Services	101,832		101,832
<b>Total Expenses</b>	<b>438,606</b>		<b>438,606</b>
Change in Net Assets Before Change in Value of Program Investment	66,948	608,534	675,482
Change in Value of Program Investment	85,824		85,824
<b>Change in Net Assets After Change in Value of Program Investment</b>	<b>152,772</b>	<b>608,534</b>	<b>761,306</b>
Net Assets as of January 1, 2016	82,870	111,466	194,336
Net Assets as of December 31, 2016	235,642	720,000	955,642

\*Other Income represents interest income.

# Executive Board and Supporters

Valerie Kerr,  
Co-Chair

Valerie Kerr has the clinical research experience, training, project management expertise, leadership skills, and motivation to steer the E-vaccine through clinical trials. Her 10-year career with one of the largest CROs in the world covers all facets of the clinical research process.

Adam MacLean,  
Co-Chair

Adam MacLean is a lifestyle consultant living in New York City. The causes he cares most about are the survival of dance in the new media landscape, the effect of HIV/AIDS on LGBT communities and chosen families, and critical dialogue about privilege and philanthropy. Adam joined the board of Abzyme Research Foundation as Chair of the Gala Committee in 2015.

Nicholas Smith,  
Treasurer

Nick Smith is a Vice President at Goldman Sachs in the Global Natural Resources group of the Investment Banking Division. Nick received a Bachelor of Commerce from the University of Melbourne and is also a Chartered Accountant as designated by the Institute of Chartered Accountants in Australia. He has served as Treasurer since September 2015.

Aimee Drouin, Esq.,  
Secretary

Aimee is the Managing Attorney of Drouin Law Offices and a devoted gay rights advocate. She graduated cum laude from Maryland Law, with a concentration on intellectual property and business law for startup biotechnology companies and non-profit organizations. Aimee became involved through a fund-raiser in NYC and decided to partner her desire to create a non-profit benefiting HIV prevention and eradication.

Zachary Barnett,  
Founder and Executive Director

In the summer of 2008 Barnett took his communication skills and passion for creating engaging events to the world of HIV research. After doing some intensive research, Barnett reached out to Dr. Sudhir Paul and his science team at the University of Texas, after seeing a CBS clip on their work on YouTube entitled "Possible HIV Cure" (the clip is the highest viewed HIV cure video on YouTube). Barnett formed a board and started the Abzyme Research Foundation a 501(c)3, and leads the push for a phase I FDA trial.

Dr. Elizabeth Miller,  
MD

Dr. Miller received her undergraduate degree at Duke University in Biomedical Engineering, and went on to medical school, internal medicine residency, and infectious diseases fellowship at NYU medical center, where she became a faculty member from 2008-2013 in the division of infectious diseases. In 2013, Dr. Miller accepted a position at Mount Sinai School of Medicine in the Division of Infectious Diseases and has served as the board's science lead since 2014.

Mike Jefvert

Raised in the Midwest, he attended both Purdue University where he received his BS in Industrial Management and Indiana University where he received his MBA in Finance. Mike has been active in Chicago's LGBT community originally as a volunteer with the Horizon Community Center Youth Group and most recently as board treasurer with Equality Illinois. During his tenure with EQIL, he witnessed both the passage of Civil Unions and Marriage Equality. With those milestones behind him, he is ready to focus his passion on helping others by supporting the work of the Abzyme Foundation.

Dave Song

David has held senior roles at Hill Holliday and JWT. Leading advertising strategies for HSBC, Subway, L.L.Bean, AOL, Verizon Wireless, USTA and American Red Cross. David sits on the board of Lambda Legal's young leaders, Housing Works, and Abzyme Research Foundation.

Tim Volk

Tim is the Founder and Principal of T.Volk & Company, a boutique advisory firm that specializes in assisting, family offices and family-controlled enterprises. He has held board positions with, The Children's Hospital at University of Illinois and Aspen Center for Integral Health. Tim holds a CFP designation. He earned a MBA from Lesley University and a Bachelor's degree in Finance from Oregon State University.

Supporters over  
\$250,000

Stansbury Family Trust, in memory of Dr. Scott Stansbury

Supporters over  
\$100,000+

Livel Foundation  
Gilead Pharmaceuticals

Supporters \$50,000+

AriZona Iced Tea

Supporters over  
\$25,000+

Stephen Mack  
Christy and John Mack Family Foundation  
Jamie Drake  
Slobodan Randelovic

Supporters \$5,000+

Gochnauer Family Foundation  
Douglas Sills  
Nicholas Smith  
Oscar Tatosian  
David Heller  
Patricia Chernicky

Contact for further information  
**ZACHARY BARNETT**  
Founder/Executive Director  
Abzyme Research Foundation  
917-338-1003  
zach@endhiv.com

Abzyme Research Foundation is a 501c3 charity located at 67 Irving Place, 12th Floor, NY, NY 10003